Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

被引：6

作者：

Bernal, Teresa ^{[1
,2
]}

Fernandez Moreno, Ainhoa ^{[1
,2
]}

de LaIglesia, Almudena ^{[3
]}

Benavente, Celina ^{[4
]}

Garcia-Noblejas, Ana ^{[5
]}

Garcia Belmonte, Daniel ^{[6
]}

Riaza, Rosalia ^{[7
]}

Salamero, Olga ^{[8
]}

Angeles Foncillas, Maria ^{[9
]}

Roldan, Alicia ^{[10
]}

Noriega Concepcion, Victor ^{[11
]}

Llorente Gonzalez, Laura ^{[12
]}

Bergua Burgues, Juan Miguel ^{[13
,16
]}

Lorente de Una, Soraya ^{[14
]}

Rodriguez-Macias, Gabriela ^{[15
]}

de la Fuente Burguera, Adolfo

Garcia Perez, Maria Jose ^{[17
]}

Lopez-Lorenzo, Jose Luis ^{[18
]}

Martinez, Pilar ^{[19
]}

Alaez, Concepcion ^{[20
]}

Callejas, Marta ^{[21
]}

Martinez-Chamorro, Carmen ^{[22
]}

Rifon Roca, Jose ^{[23
]}

Amador Barciela, Lourdes ^{[24
]}

Mena Duran, Armando V. ^{[25
]}

Gomez Correcha, Karoll ^{[26
]}

Lavilla Rubira, Esperanza ^{[27
]}

Luz Amigo, Maria ^{[28
]}

Vall-llovera, Ferran ^{[29
]}

Garrido, Ana ^{[30
]}

Garcia-Fortes, Maria ^{[31
]}

de Miguel Llorente, Dunia ^{[32
]}

Aules Leonardo, Anastasia ^{[33
]}

Cervero, Carlos ^{[34
]}

Coll Jorda, Rosa ^{[35
]}

Perez-Encinas, Manuel M. ^{[36
]}

Polo Zarzuela, Marta ^{[4
]}

Figuera, Angela ^{[5
]}

Rad, Guillermo ^{[2
]}

Martinez-Cuadron, David ^{[37
]}

Montesinos, Pau

机构：

[1] Hosp Univ Cent Asturias, Oviedo, Spain

[2] Inst Invest Principado Asturias ISPA, Inst Oncol Principado Asturias IUOPA, Oviedo, Spain

[3] Hosp Puerta Hierro, Madrid, Spain

[4] Hosp Clin San Carlos, Madrid, Spain

[5] Hosp La Princesa, Madrid, Spain

[6] Hosp Univ Sanitas Zarzuela, Madrid, Spain

[7] Hosp Univ Severo Ochoa, Madrid, Spain

[8] Hosp Valle De Hebron, Barcelona, Spain

[9] Hosp Infanta Leonor, Madrid, Spain

[10] Univ Europea, Hosp Infanta Sofia San Sebastian de los Reyes, Dept Med, Madrid, Spain

[11] Complejo Hosp Univ A Coruna, La Coruna, Spain

[12] Hosp Univ HM Sanchinarro, Madrid, Spain

[13] Hosp San Pedro Alcantara, Caceres, Spain

[14] Hosp Vithas Xanit Int, Malaga, Spain

[15] Hosp Gregorio Maranon, Madrid, Spain

[16] MD Anderson Canc Ctr, Madrid, Spain

[17] Complejo Hosp Torre Cardenas, Almeria, Spain

[18] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[19] Hosp Univ Doce Octubre, Madrid, Spain

[20] Hosp Univ Moncloa, Madrid, Spain

[21] Hosp Univ Principe Asturias, Madrid, Spain

[22] Hosp Univ Quiron Pozuelo, Madrid, Spain

[23] Clin Univ Navarra, Pamplona, Spain

[24] Complejo Hosp Pontevedra, Pontevedra, Spain

[25] Consorcio Hosp Gen Univ Valencia, Valencia, Spain

[26] Hosp Juan Ramon Jimenez, Huelva, Spain

[27] Hosp Lucus Augusti, Lugo, Spain

[28] Hosp Gen Univ Morales Messeguer, Murcia, Spain

[29] Hosp Mutua Tarrasa, Barcelona, Spain

[30] Hosp Santa Creu i Sant Pau, Barcelona, Spain

[31] Hosp Univ Virgen Victoria, Malaga, Spain

[32] Hosp Univ Guadalajara, Guadalajara, Spain

[33] Hosp Miguel Servet, Zaragoza, Spain

[34] Hosp Virgen Luz, Cuenca, Spain

[35] Hosp Univ Dr Josep Trueta, ICO Girona, Girona, Spain

[36] Hosp Univ Santiago Compostela, Santiago, Spain

[37] Hosp Univ & Politecn La Fe, Valencia, Spain

来源：

CANCER MEDICINE | 2023年 / 12卷 / 14期

关键词：

acute myeloid leukemia; clinical observations; intensive chemotherapy; real-world; OLDER PATIENTS; SECONDARY; RECOMMENDATIONS; DIAGNOSIS; FEATURES; AML;

D O I：

10.1002/cam4.6120

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real-life patients. Methods: Retrospective analysis of AML patients treated with CPX-351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry. Results: Median age of 79 patients treated with CPX-351 was 67 years old (interquartile range 62-71), 53 were MRC-AML. The complete remission (CR) rate or CR without recovery (CRi) after 1 or 2 cycles of CPX-351 was 52%, 60-days mortality 18%, measurable residual disease <0.1% in 54% (12 out of 22) of them. Stem cell transplant (SCT) was performed in 27 patients (34%), median OS was 10.3 months, and 3-year relapse incidence was 50%. Using PSM, we obtained two comparable cohorts treated with CPX-351 (n = 52) or IC (n = 99), without significant differences in CR/CRi (60% vs. 54%) and median OS (10.3 months vs. 9.1 months), although more patients were bridged to SCT in the CPX-351 group (35% vs. 12%). The results were confirmed when only 3 + 7 patients were included in the historical cohort. In multivariable analyses, SCT was associated with better OS (HR 0.33 95% CI: 0.18-0.59), p < 0.001. Conclusion: Larger post-authorization studies may provide evidence of the clinical benefits of CPX-351 for AML in the real-life setting.

引用

页码：14892 / 14901

页数：10

共 17 条

[1] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[2] Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort [J].

Chiche, Edmond ;

Rahme, Ramy ;

Bertoli, Sarah ;

Dumas, Pierre-Yves ;

Micol, Jean-Baptiste ;

Hicheri, Yosr ;

Pasquier, Florence ;

Peterlin, Pierre ;

Chevallier, Patrice ;

Thomas, Xavier ;

Loschi, Michael ;

Genthon, Alexis ;

Legrand, Ollivier ;

Mohty, Mohamad ;

Raffoux, Emmanuel ;

Auberger, Patrick ;

Caulier, Alexis ;

Joris, Magalie ;

Bonmati, Caroline ;

Roth-Guepin, Gabrielle ;

Lejeune, Caroline ;

Pigneux, Arnaud ;

Vey, Norbert ;

Recher, Christian ;

Ades, Lionel ;

Cluzeau, Thomas .

BLOOD ADVANCES, 2021, 5 (01) :176-184

[3] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[4] CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program [J].

Guolo, Fabio ;

Fianchi, Luana ;

Minetto, Paola ;

Clavio, Marino ;

Gottardi, Michele ;

Galimberti, Sara ;

Rizzuto, Giuliana ;

Rondoni, Michela ;

Bertani, Giambattista ;

Dargenio, Michela ;

Bilio, Atto ;

Scappini, Barbara ;

Zappasodi, Patrizia ;

Scattolin, Anna Maria ;

Grimaldi, Francesco ;

Pietrantuono, Giuseppe ;

Musto, Pellegrino ;

Cerrano, Marco ;

D'Ardia, Stefano ;

Audisio, Ernesta ;

Cignetti, Alessandro ;

Pasciolla, Crescenza ;

Pavesi, Francesca ;

Candoni, Anna ;

Gurreri, Carmela ;

Morselli, Monica ;

Alati, Caterina ;

Fracchiolla, Nicola ;

Rossi, Giovanni ;

Caizzi, Manuela ;

Carnevale-Schianca, Fabrizio ;

Tafuri, Agostino ;

Rossi, Giuseppe ;

Ferrara, Felicetto ;

Pagano, Livio ;

Lemoli, Roberto Massimo .

BLOOD CANCER JOURNAL, 2020, 10 (10)

[5] Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry [J].

Hulegardh, Erik ;

Nilsson, Christer ;

Lazarevic, Vladimir ;

Garelius, Hege ;

Antunovic, Petar ;

Rangert Derolf, Asa ;

Mollgard, Lars ;

Uggla, Bertil ;

Wennstrom, Lovisa ;

Wahlin, Anders ;

Hoglund, Martin ;

Juliusson, Gunnar ;

Stockelberg, Dick ;

Lehmann, Soren .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (03) :208-214

[6] CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia [J].

Lancet, Jeffrey E. ;

Uy, Geoffrey L. ;

Cortes, Jorge E. ;

Newell, Laura F. ;

Lin, Tara L. ;

Ritchie, Ellen K. ;

Stuart, Robert K. ;

Strickland, Stephen A. ;

Hogge, Donna ;

Solomon, Scott R. ;

Stone, Richard M. ;

Bixby, Dale L. ;

Kolitz, Jonathan E. ;

Schiller, Gary J. ;

Wieduwilt, Matthew J. ;

Ryan, Daniel H. ;

Hoering, Antje ;

Banerjee, Kamalika ;

Chiarella, Michael ;

Louie, Arthur C. ;

Medeiros, Bruno C. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) :2684-+

[7] Modeling survival data: Extending the Cox model. [J].

Li, JCA .

SOCIOLOGICAL METHODS & RESEARCH, 2003, 32 (01) :117-120

[8] Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy [J].

Martinez-Cuadron, D. ;

Montesinos, P. ;

Vellenga, E. ;

Bernal, T. ;

Salamero, O. ;

Holowiecka, A. ;

Brunet, S. ;

Gil, C. ;

Benavente, C. ;

Ribera, J. M. ;

Perez-Encinas, M. ;

De la Serna, J. ;

Esteve, J. ;

Rubio, V. ;

Gonzalez-Campos, J. ;

Escoda, L. ;

Amutio, M. E. ;

Arnan, M. ;

Arias, J. ;

Negri, S. ;

Lowenberg, B. ;

Sanz, M. A. .

LEUKEMIA, 2018, 32 (01) :21-29

[9] Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study [J].

Ostgard, Lene Sofie Granfeldt ;

Medeiros, Bruno C. ;

Sengelov, Henrik ;

Norgaard, Mette ;

Andersen, Mette Klarskov ;

Dufva, Inge Hogh ;

Friis, Lone Smidstrup ;

Kjeldsen, Eigil ;

Marcher, Claus Werenberg ;

Preiss, Birgitte ;

Severinsen, Marianne ;

Norgaard, Jan Maxwell .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3641-+

[10] Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia [J].

Pagano, L ;

Pulsoni, A ;

Tosti, ME ;

Avvisati, G ;

Mele, L ;

Mele, A ;

Martino, B ;

Visani, G ;

Cerri, R ;

Di Bona, E ;

Invernizzi, R ;

Nosari, A ;

Clavio, M ;

Allione, B ;

Coser, P ;

Candoni, A ;

Levis, A ;

Camera, A ;

Melillo, L ;

Leone, G ;

Mandelli, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) :109-117

← 1 2 →